| Drug |
Pharmacological Action |
Route(s) of Administration |
Success |
Adverse Events |
Dose |
|
| Phenylephrine |
Pure 1-adrenergic agonist |
Intracorporeal injection |
Yes |
Lack of positive cardiac inotropism or chronotropism, decrease in cardiac
output, increase in mean arterial pressure, bradycardia rarely |
100500 µg |
| Epinephrine |
1-adrenergic agonist |
Intracorporeal injection |
Yes |
Inotropism or chronotropism |
1020 µg |
| Ketamine |
Dissociative anesthetic (unknown mode action) |
Intravenously |
No |
Time for flaccidity to develop, hallucinations |
0.51 mg/kg |
| Amylnitrate |
Vascular smooth muscle relaxant |
Inhalation |
No |
Serious complications in elderly patients |
0.3 mL |
| Terbutaline |
ß2-adrenergic agonist |
Per os, subcutaneously, intravenously |
Yes (with caution) |
Tachycardia, pulmonary edema, hypokalemia |
5 mg per os/0.250.5 mg subcutaneously or intravenously |
Other -adrenergic agonists (nor-adrenaline, metaraminol, etilnephrine) |
-adrenergic agonists |
Intracorporeal injection, intravenously |
Yes |
Hypertensive crisis, pulmonary edema, rupture of aneurysms, additional
ß1 activity |
In case |